Olpasiran (AMG890) is an experimental antisense therapy designed to lower the level of lipoprotein(a), which is believed to be a causal factor in the development of cardiovascular disease. The drug is developed by Amgen.[1][2]
References
- ^ O’Donoghue, Michelle L.; Rosenson, Robert S.; Gencer, Baris; López, J. Antonio G.; Lepor, Norman E.; Baum, Seth J.; Stout, Elmer; Gaudet, Daniel; Knusel, Beat; Kuder, Julia F.; Ran, Xinhui; Murphy, Sabina A.; Wang, Huei; Wu, You; Kassahun, Helina; Sabatine, Marc S. (17 November 2022). "Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease". New England Journal of Medicine. 387 (20): 1855–1864. doi:10.1056/NEJMoa2211023.
- ^ Koren, Michael J.; Moriarty, Patrick Maurice; Baum, Seth J.; Neutel, Joel; Hernandez-Illas, Martha; Weintraub, Howard S.; Florio, Monica; Kassahun, Helina; Melquist, Stacey; Varrieur, Tracy; Haldar, Saptarsi M.; Sohn, Winnie; Wang, Huei; Elliott-Davey, Mary; Rock, Brooke M.; Pei, Tao; Homann, Oliver; Hellawell, Jennifer; Watts, Gerald F. (January 2022). "Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)". Nature Medicine. 28 (1): 96–103. doi:10.1038/s41591-021-01634-w. ISSN 1546-170X.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 17 January 2024, at 01:20